Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: Seer-medicare trends 1991 to 1999

Urology

Volumn 64, Issue 6, 2004, Pages 1171-1176

  Zeliadt, Steven B ^a,b   Potosky, Arnold L ^c   Etzioni, Ruth ^a,b   Ramsey, Scott D ^a,b   Penson, David F ^a,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GONADORELIN AGONIST;

AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER REGISTRY; CANCER SURVIVAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNOLOGY; EUROPEAN AMERICAN; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; MULTIMODALITY CANCER THERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH INSURANCE; RACE DIFFERENCE; SOCIOECONOMICS; TREATMENT INDICATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEDICARE; PROSTATIC NEOPLASMS; SEER PROGRAM; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 10644262092     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.07.037     Document Type: Article

References (30)

1. J.M. Legler, E.J. Feuer, A.L. Potosky The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States Cancer Causes Control 9 1998 519 527
2. R. Etzioni, K.M. Berry, J.M. Legler Prostate-specific antigen testing in black and white men an analysis of Medicare claims from 1991-1998 Urology 59 2002 251 255
3. R.Y. Demers, A. Tiwari, J. Wei Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality Cancer 92 2001 2309 2317
4. P.C. Albertsen The prostate cancer conundrum J Natl Cancer Inst 95 2003 930 931
5. M.R. Cooperberg, G.D. Grossfeld, D.P. Lubeck National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989
6. L. Harlan, O. Brawley, F. Pommerenke Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate J Clin Oncol 13 1995 93 100
7. J.L. Warren, C.N. Klabunde, D. Schrag Overview of the SEER-Medicare data content, research applications, and generalizability to the United States elderly population Med Care 40 2002 IV-3 IV-18
8. B.A. Virnig, J.L. Warren, G.S. Cooper Studying radiation therapy using SEER-Medicare-linked data Med Care 40 2002 IV-49 IV-54
9. T. Bubolz, J.H. Wasson, G. Lu-Yao Treatments for prostate cancer in older men 1984-1997 Urology 58 2001 977 982
10. J. Brandeis, C.L. Pashos, J.M. Henning A nationwide charge comparison of the principal treatments for early stage prostate carcinoma Cancer 89 2000 1792 1799
11. G.L. Lu-Yao, A.L. Potosky, P.C. Albertsen Follow-up prostate cancer treatments after radical prostatectomy a population-based study J Natl Cancer Inst 88 1996 166 173
12. R.J. Klein, C.A. Schoenborn Age adjustment using the 2000 projected U.S. population Healthy People 2010 Stat Notes, No. 20 2001 National Center for Health Statistics Hyattsville, Maryland 1 10
13. C.N. Klabunde, A.L. Potosky, J.M. Legler Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267
14. W. Underwood, S. De Monner, P. Ubel Racial/ethnic disparities in the treatment of localized/regional prostate cancer J Urol 171 2004 1504 1507
15. F.J. Fowler, M. McNaughton Collins, P.C. Albertsen Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer JAMA 283 2000 3217 3222
16. L.M. Ellison, J.A. Heaney, J.D. Birkmeyer Trends in the use of radical prostatectomy for treatment of prostate cancer Effect Clin Pract 2 1999 228 233
17. C.J. Mettlin, G.P. Murphy, D.S. Rosenthal for the American College of Surgeons Commission on Cancer and the American Cancer Society The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. Cancer 83 1998 1679 1684
18. C.N. Klabunde, A.L. Potosky, L.C. Harlan Trends and black/white differences in treatment for nonmetastatic prostate cancer Med Care 36 1998 1337 1348
19. V.L. Shavers, M.L. Brown Racial and ethnic disparities in the receipt of cancer treatment J Natl Cancer Inst 94 2002 334 357
20. A.L. Potosky, K. Knopf, L.X. Clegg Quality-of-life outcomes after primary androgen deprivation therapy results from the Prostate Cancer Outcomes Study J Clin Oncol 19 2001 3750 3757
21. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
22. Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council Trial Br J Urol 79 1997 235 246
23. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) a phase III randomised trial Lancet 360 2002 103 106
24. J.W. Moul, I.A. Sesterhenn, R.R. Connelly Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men JAMA 274 1995 1277 1281
25. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
26. E.M. Messing, J. Manola, M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
27. H.W. Herr, M. O'Sullivan Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy J Urol 163 2000 1743 1746
28. H.W. Daniell Osteoporosis due to androgen deprivation therapy in men with prostate cancer Urology 58 2001 101 107
29. A.L. Potosky, B.B. Reeve, L.X. Clegg Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy J Natl Cancer Inst 94 2002 430 437
30. J.H. Wasson, F.J. Fowler, M.J. Barry Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era a national survey of urologist beliefs and practices J Urol 159 1998 1993 1997